Psyence Biomed Expands Clinical Trials for Psilocybin Treatment
Psyence Biomedical Ltd. (NASDAQ: PBM), a pioneering company in the field of biotechnology, recently made significant strides by announcing the recruitment of the Empax Center as the second clinical trial site for its ongoing Phase IIb clinical trial. This study focuses on the use of nature-derived psilocybin as a potential treatment for Adjustment Disorder, particularly in patients receiving palliative care.
Empax Center Joins the Clinical Trial Initiative
Empax Center, located in Perth, Australia, is known for its cutting-edge facilities and expertise in executing mental health clinical trials. By partnering with this center, Psyence Biomed aims to enhance the efficiency of patient recruitment and treatment processes for the ongoing study. The company is excited to initiate treatments shortly, with the goal of generating topline data by the latter half of 2025.
Statements from Leadership
Dr. Clive Ward-Able, the Medical Director at Psyence Biomed, expressed his enthusiasm regarding the partnership, stating, "Incorporating Empax Center into our trial signifies a monumental step. Their specialization in mental health treatments, including psychedelic-assisted therapies, is invaluable in expediting our clinical study."
Michael Winlo, CEO of Empax Center, also conveyed his excitement, highlighting the trial's potential to revolutionize care for patients grappling with significant existential stress due to terminal illnesses. He noted, "Our center is committed to providing the best possible care combined with innovative treatment options. We are eager to ensure a positive experience for all trial participants, bolstered by the expertise of our dedicated team."
The Role of iNGEN? and Ongoing Preparations
Psyence Biomed has previously announced partnerships with Fluence, a leader in psychedelic therapy education, and iNGEN? CRO Pty Ltd, a clinical research organization in Australia. These collaborations are instrumental in supporting the study's progression. Recently, the successful export of the drug product PEX010 to Australia marked another crucial step in preparing for the trial's initiation. With patient screening set to commence soon, the first participant is expected to be enrolled by early December.
About Empax Center
Empax Center is a state-of-the-art facility dedicated to guiding the potential of emerging treatments for serious mental health conditions, particularly those related to palliative care. This facility is staffed by experienced professionals, including several of Australia's first authorized prescribers of psychedelic-assisted therapies, all committed to advancing research and enhancing patient care.
About Psyence Biomed
Psyence Biomed is a trailblazer as the first life sciences biotechnology company developing nature-derived psilocybin-based psychedelic medicines listed on Nasdaq. Their focus is on addressing the urgent needs of patients suffering from mental health disorders, particularly within palliative settings. The name "Psyence" reflects their commitment to blending scientific rigor with innovative psychedelic treatments, aiming to create effective, regulatory-compliant solutions for various mental health challenges.
Contact Information
If you have any inquiries, you can reach Psyence Biomed via email at ir@psyencebiomed.com or contact their media team at media@psyencebiomed.com. General information can be addressed to info@psyencebiomed.com. For investor relations, reach out to Jeremy Feffer at jfeffer@lifesciadvisors.com or call +1 416-477-1708.
Frequently Asked Questions
What is the primary focus of the Psyence Biomed clinical trial?
The clinical trial focuses on evaluating the effectiveness of nature-derived psilocybin as a treatment for Adjustment Disorder in palliative care settings.
What makes Empax Center a valuable trial site for Psyence Biomed?
Empax Center specializes in mental health treatments and has a state-of-the-art facility, making it ideal for conducting this important clinical trial.
When will the trial begin enrolling participants?
Patient screening is expected to commence soon, with the first participant likely to be enrolled by early December.
What are the future goals for Psyence Biomed following this trial?
Should the trial produce favorable results, Psyence Biomed aims to initiate pivotal registrational studies for their psilocybin treatments.
How can patients participate in the Psyence Biomed trial?
Interested patients should contact Empax Center or consult with their healthcare provider for more information on participation in the study.
